Time filter

Source Type

Palo Alto, CA, United States

Huang X.,Shanghai JiaoTong University | Huang X.,University of Houston | Dorta-Estremera S.,University of Houston | Yao Y.,Cellular Biomedicine Group (CBMG) | And 3 more authors.
Frontiers in Immunology | Year: 2015

Plasmacytoid dendritic cells (pDCs), which are prominent type I interferon (IFN-I)-producing immune cells, have been extensively implicated in systemic lupus erythematosus (SLE). However, whether they participate critically in lupus pathogenesis remains unknown. Recent studies using various genetic and cell type-specific ablation strategies have demonstrated that pDCs play a pivotal role in the development of autoantibodies and the progression of lupus under diverse experimental conditions. The findings of several investigations highlight a notion that pDCs operate critically at the early stage of lupus development. In particular, pDCs have a profound effect on B-cell activation and humoral autoimmunity in vivo. This deeper understanding of the vital role of pDCs in lupus pathogenesis supports the therapeutic targeting of the pDC-IFN-I pathway in SLE. © 2015 Huang, Dorta-Estremera, Yao, Shen and Cao. Source

Yao X.,U.S. National Institutes of Health | Yao X.,Cellular Biomedicine Group (CBMG) | Lu Y.-C.,U.S. National Institutes of Health | Parker L.L.,U.S. National Institutes of Health | And 9 more authors.
Journal of Immunotherapy | Year: 2016

Long-term tumor regressions have been observed in patients following the adoptive transfer of autologous tumorinfiltrating lymphocytes or genetically modified T cells expressing MHC class I-restricted T-cell receptors (TCRs), but clinical trials have not evaluated responses to genetically modified T cells expressing antitumor MHC class II-restricted TCRs. As studies carried out in a murine tumor model system have demonstrated that the adoptive transfer of CD4+ T cells could lead to the regression of established tumors, we plan to test the hypothesis that CD4+ T cells can also induce tumor regressions in cancer patients. In this study, 2 MAGE-A3-specific TCRs were isolated from a regulatory T-cell clone (6F9) and an effector clone (R12C9), generated from the peripheral blood of 2 melanoma patients after MAGE-A3 vaccination. The results indicated that T cells transduced with 6F9 TCR mediated stronger effector functions than R12C9 TCR. The 6F9 TCR specifically recognized MAGE-A3 and the closely related MAGE-A6 gene product, but not other members of the MAGE-A family in the context of HLA-DPB1∗04:01. To test the feasibility of a potential clinical trial using this TCR, a clinical-scale procedure was developed to obtain a large number of purified CD4+ T cells transduced with 6F9 TCR. Because HLADPB1∗ 04:01 is present in B60% of the Caucasian population and MAGE-A3 is frequently expressed in a variety of cancer types, this TCR immunotherapy could potentially be applicable for a significant portion of cancer patients. © 2016 Wolters Kluwer Health, Inc. All rights reserved. Source

Cellular Biomedicine Group (CBMG) | Entity website

Cellular Biomedicine Group (CBMG) | Entity website

COMPANY HIGHLIGHTS Robust product pipelines addressing multiple large market opportunities Highly experienced executive and scientific team GMP-certified facilities in the PRC designed to international, U.S ...

Cellular Biomedicine Group (CBMG) | Entity website

Please choose a page from the left menu to learn About Us in detail

Discover hidden collaborations